Breaking Research News from sources other than Breastcancer.org
Comments
-
MOTH
Sad report. I don’t even have to read the report to believe that. Those figures pan out in clinical trial reports and even the latest news drugs. Why do they spend so much money on a drug that only gets us OSR of about 3 months (median)
Because of the hope you are one of the few on the outlying edge of the numbers like my sister. She started on opdivo for NSCLC when it first came out and has survived with stable disease for 5 years and going strong.
If they don’t keep trying, they won’t find the right one! I’m thankful for the effort and hope the next breakthrough is the one!
Dee
0 -
oligometastatic peeps -
improved OS for those who had surgical resection of primary and oligomets
https://drive.google.com/file/d/18yi0zQK0L4oP5WY4T...
0 -
Moth,
Do you have another link for that article? I can't get it to load -- I just get the spinning wheel. Or do you have an exact title so we can find it ourselves?
Thanks
0 -
weird I just checked and it's working for me. It's a poster presentation ahead of publication from sabcs.
Someone tweeted a lower quality version here but it doesn't blow up nicely https://twitter.com/stage4kelly/status/13367092193...
0 -
Thanks. That one worked for me and I was able to blow it up a bit from twitter.
0 -
BevJen, there's been a google problem that includes documents. If you try again later, it might work fine.
0 -
Physicians Commonly Miss Adverse Events in Patients With Breast Cancer
Physicians commonly underrecognized adverse events of pain, pruritus, edema, and fatigue that patients with breast cancer experienced after radiotherapy, found a study presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS).
The study included 9868 patients from 29 practices in Michigan who had breast cancer and received radiotherapy after lumpectomy.
Study researchers reviewed 37,593 reports of pain, pruritus, edema, and fatigue from patient reports and compared them with the grade physicians gave the adverse events. Physicians graded adverse events using the Common Toxicity Criteria for Adverse Events (CTCAE).
Physicians were considered to underrecognize pain if they graded the severity as 0 — that is, absent — and the patient reported the severity as moderate, or if they graded the severity as 1 or lower and the patient reported the severity as severe. Pruritis and edema were considered underrecognized if physicians graded the severity as 0 and patients reported bother often or all of the time. Fatigue was considered underrecognized if physicians graded the severity as 0 and patients reported having significant fatigue most of the time or always.
Compared with White patients, Black patients had a 92% increased odds of having adverse events underrecognized (odds ratio [OR], 1.92; 95% CI, 1.65-2.23; P <.001).
Compared with patients aged 60 to 69 years, patients who were younger than 50 years had a 35% increased odds of having adverse events underrecognized (OR, 1.4).
"We need to do a better job — that's really what it is," commented SABCS Codirector Virginia Kaklamani, MD, UT Health San Antonio MD Anderson Cancer Center, Texas. "We need to conduct studies where patient-reported outcomes are being reported, and we as physicians need to listen more to our patients."
https://www.cancertherapyadvisor.com/home/news/con...
Reference: Jagsi R, Griffith KA, Vicini F, et al. Identifying patients whose symptoms are under-recognized during breast radiotherapy: comparison of patient and physician reports of toxicity in a multicenter cohort. Presented at: 2020 Virtual San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract GS3-07.
{Stunningly insightful. Many of us have complained about similar issues for years. Access to reporting is at no charge but may require log-in. Not sure about access parameters for prezo. Log in for SABCS may be required.}
0 -
Radiation From Wireless Devices May Cause Breast Cancer, New Study Shows
https://childrenshealthdefense.org/defender/radiation-wireless-devices-may-cause-breast-cancer/
0 -
Posted this on an exercise thread but I think it's worth posting here too.
Physical activity of any intensity, whether folding laundry or jogging, can lower the risk of an early death for middle-aged and older people, a new study suggests. Furthermore, the time of day you move your body could affect risk further.
Researchers analyzed data from 2,795 participants. They identified a group of 781 women with breast
cancer and 865 female controls, and a group of 504 men with prostate cancer and 645 male controls. Both groups responded to a questionnaire relating to their physical activities and gave data on the timing and frequency of their exercises.
The study found that exercising in the morning, between 8-10 a.m., showed the highest benefit in reducing the risk of both breast and prostate cancers. Researchers also found that men who exercised between the hours of 7 and 10 p.m. had a 25 percent lower risk of developing prostate cancer. No benefits from evening activity were seen in the group of women.
"Overall our findings indicate that time of the day of physical activity is an important aspect of physical activity that may potentiate the protective effect of physical activity on cancer risk," the researchers wrote. "The effect of timing of physical activity on cancer risk should be examined in future research with a more detailed assessment of activity patterns, also including occupational activity."
https://onlinelibrary.wiley.com/doi/10.1002/ijc.333100 -
Complementing the post above is a study in Kenya advocating the benefits of exercise and diet in lowering the risk of BC
0 -
Interesting BlueGIrl.
0 -
this is interesting, it's from a Phase 2b Trial.
https://www.onclive.com/view/gp2-gm-csf-combo-elic...
The GP2 immunotherapy plus granulocyte-macrophage colony-stimulating factor demonstrated potent responses and a 100% disease-free survival in patients with HER2/neu 3–positive disease who received adjuvant trastuzumab.
Says there's a Phase 3 Trial Coming
0 -
Alpha-TEA [in phase 1 trial] strikes down advanced breast cancer?
..."The patients with HER2 driven or positive breast cancer, they actually start losing these T-cells and so they lose that immunologic response," explained William Gwin, MD, an assistant professor at University of Washington School of Medicine and breast cancer specialist at Seattle Cancer Care Alliance.
But now a phase one clinical trial is underway with advanced HER2 positive breast cancer patients for the oral therapy alpha-TEA in combination with the antibody-drug Herceptin. Alpha-TEA works by activating T-cells.
"We can boost those and drive those T-cells that target HER2 and sort of restore that immune response against HER2," elaborated Dr. Gwin.
Attacking cancer cells but leaving the normal cells alone.
"It does seem to have similar effects to chemotherapy, but really without the side effects," Dr. Gwin shared.
https://www.wmcactionnews5.com/2020/12/15/best-life-alpha-tea-strikes-down-advanced-breast-cancer/
0 -
Dear Debbew, this is crazily good news...
It is interesting what dosages they use (they do not say this in clinical trial)? I already found they use up to 1500 mg/kg/day in dogs:) Saulius0 -
Found it: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.TPS1103 Saulius
0 -
Thanks for adding that info, Saulius!
0 -
HER2 people, FDA approves Margetuximab!
https://www.onclive.com/view/fda-approves-margetux...
Debbew, I tried to look if one can buy alpha-TEA:) No luck - probably a serious agent, although well known for at least a decade. Actually my motivation is based on assumption that this is something "promising", as they never had clinical trials with alpha-TEA in BC patients, and now start directly with ABC (well, there's evidence in dishes with cell lines). And it is strange this substance is not widely out there, as it is a derivative of vitE. I surely can find folks who could synthesize it here in labs:)) but it would be idiotic to use it without quality control. Trastuzumab resistance is real and it would be so cool to overcome it with this "simple" compound...
Saulius
0 -
-
Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer.
Harold J. Burstein, M.D., Ph.D.
Some of the txt:
In recent years, the options for adjuvant endocrine treatment have broadened beyond tamoxifen. Aromatase inhibitors block the conversion of androgens into estrogens (Figure 1), suppressing residual estrogen levels by more than 90% in postmenopausal women. These agents are contraindicated in premenopausal women who are not undergoing ovarian suppression, because compensatory physiological responses induce ovarian estrogen production. Aromatase inhibitor therapy results in a greater reduction in the risk of recurrence than 5 years of tamoxifen, such that most postmenopausal women should consider aromatase inhibitor treatment either as initial therapy or after 2 to 3 years of tamoxifen. For women presenting with stage I or IIA cancers — the most common stage at diagnosis in countries where screening mammography is routine — the numerical advantage of aromatase inhibitor–based treatment over tamoxifen alone is modest: a 3% reduction in recurrence and a 2% reduction in mortality at 10 years. Aromatase inhibitors are of more value in the treatment of higher-risk cancers (according to stage or biologic features) because of the underlying prognosis39 and in the treatment of lobular cancers. Extending the duration of treatment from 5 to 10 years with either tamoxifen41 or aromatase inhibitors reduces the risk of recurrence, as compared with just 5 years of treatment. Patients at increased risk for a late recurrence because of nodal status or adverse biologic features of the tumor probably derive the greatest benefit from extended therapy; however, extended aromatase inhibitor treatment in years 8 through 10 is likely to confer a modest benefit, at most. The decision to extend therapy should incorporate the patient's preferences, informed by the estimated risk of recurrence beyond year 5, and the toxic effects of therapy to date (Figures 3 and Figure 4).
0 -
How about this?
Nanoparticle Trains Immune Cells to Attack Cancer
0 -
Cleveland Clinic [triple negative] Breast Cancer Vaccine Goes To Clinical Trials
The shot protects against alpha-lactalbumin, a protein in women's mammary glands that no longer appears after childbearing years but shows up in many cases of triple negative breast cancer, [Dr. Vincent Tuohy, a cancer researcher at the clinic who invented the vaccine] said.
The idea behind taking this vaccine is the body's immune response would destroy cancer cells before they develop and mature, Tuohy said...
In animal trials, the vaccine was shown to be very effective, Tuohy added...
If the trials are successful, Tuohy said he hopes people could eventually get the vaccine as part of their normal preventative care.
0 -
Interesting article from the National Cancer Institute about exceptional responders --what they've found out so far.
https://www.cancer.gov/news-events/press-releases/...
0 -
I have stage one and had a lumpectomy and just finished radiation. Does anyone know The name of the blood test that shows how many circulating tumor cells are in a persons blood? And is it possible to get that number down to 0? And if it gets down to 0 can aperson stop taking whatever inhibitor they are taking? Just wondering if anybody has had experience with this. Thank you.
0 -
Springdaisy - Signatera is one brand of the CTC test. AFAIK we don't have enough studies to show if 0 means you can go off hormone therapy.
Breast Cancer Index measures risk of recurrence but it's for AFTER 5 yrs of hormone therapy to see if hormone therapy should be extended. It's not FDA approved. https://www.breastcancer.org/symptoms/testing/type...
0 -
moth, thank you for the info. How could you have stage four if you only had stage one three years ago? My god that’s scary.
0 -
Hi Springdaisy - I guess I drew the short straw. When I ran the stats in Predict https://breast.predict.nhs.uk/tool 89% of women with my stats were alive at 5 years. I used that as a proxy for metastatic recurrence... so 1/10 like me would recur with terminal disease. Tried to do my best to lessen the risk - the only evidence based interventions seem to be exercise and maybe green tea. I did that. I exercised before I got stage 1 too so didn't work then either. Didn't work to prevent progression so I guess there's some powerful cancer genetics at work & I got to be one out of 10
triple neg has a different mets timeline than hormone positive. We're more likely to recur at all but if we do, it's in the first 5 years so if we make it past 5, the risk starts falling. Hormone positive has this long tail of ongoing risk so a different risk profile. This cancer thing sucks all around & part of what's missing in breast cancer discussions is that it still kills very many of us. So much talk of 'survivors' and pink ribbons that sometimes it's easy to forget it's fatal to many.
0 -
thank you for replying, moth. I wish you and everybody in this forum the best of luck. Yes, you are right, cancer sucks no matter what kind. Someone brought up the point the other day that they have rushed through the Covid vaccine so what about rushing through cures for cancer and other things? I never thought of it before but that’s a very good point. Although I don’t want cures that have been rushed through the system but they claim Covid was tested upon thousands of people and went by the rules of the CDC.
0 -
The trouble is cancer is not a disease any more than "virus" is a disease. Even within breast cancer effective treatments are radically different for all the different subtypes. So there will never be one cure for "cancer" any more than there will be one cure for all viruses, from cold viruses to polio to HIV.
I just finished a year and a half of chemo, which brings my 3 year "risk" of disease-free survival to 89% Improved, but not great.
My oncologist is very honest with me, "the only way to know you are a survivor is to die of something else" Breast cancers suck.
0 -
Anyone heard about this? Sounds great, I love to see a bigger trial group though.
https://www.targetedonc.com/view/fda-grants-fast-track-designation-for-her2-positive-metastatic-breast-cancer“A clinical update on ARX788 was announced in December during a presentation for the 2020 San Antonio Breast Cancer Symposium (SABCS) demonstrated an objective response rate (ORR) of 74% with ARX788 in the phase 1 HER2-positive breast cancer trial in China, which included responses in 14 of 19 patients and a disease control rate (DCR) of 100%. The ORR was 67% in the phase 1 HER2-positive pan tumor trial in the United States and Australia with responses in 2 of 3 patients and a DCR of 100%. Both these findings were found with the 1.5 mg/kg dose.2“
0 -
Preliminary study of how adiposity influences breast cancer biology, treatment resistance, and disease progression shows High BMI related to effectiveness of doxataxel!
This is a surprise revelation and shocking to me, 😳 Since my BMI was much higher when I was on taxotere. Hope they study this more.Dee
0
![[Deleted User]](https://us.v-cdn.net/6037276/uploads/defaultavatar/nF0ALO3I3QJM7.jpg)
